Aniquinazolines A–D, Four New Quinazolinone Alkaloids from Marine-Derived Endophytic Fungus Aspergillus nidulans

Chun-Yan An 1,2, Xiao-Ming Li 1, Chun-Shun Li 1, Ming-Hui Wang 1,2, Gang-Ming Xu 1 and Bin-Gui Wang 1,*

Abstract: Four new quinazolinone alkaloids, namely, aniquinazolines A–D (1–4), were isolated and identified from the culture of Aspergillus nidulans MA-143, an endophytic fungus obtained from the leaves of marine mangrove plant Rhizophora stylosa. The structures of the new compounds were elucidated by spectroscopic analysis, and their absolute configurations were determined on the basis of chiral HPLC analysis of the acidic hydrolysates. The structure for 1 was confirmed by single-crystal X-ray diffraction analysis. All these compounds were examined for antibacterial and cytotoxic activity as well as brine shrimp (Artemia salina) lethality.

Keywords: mangrove; endophytic fungus; Aspergillus nidulans; secondary metabolites; bioactivity

1. Introduction

Quinazolinone derivatives generally refer to the compounds possessing a building block of quinazolin-4-one. More than 160 naturally occurring quinazolinones have been isolated from different organisms including plants, animals and microorganisms [1]. This family of alkaloids has attracted great
attention due to their diversified structures and potent biological activities such as cytotoxicity, anti-feedant, and anti-microbial activities [2–9]. It is notable that some quinazolinone derivatives biogenetically synthesized by nonribosomal peptide synthesis (NRPS) [10] were isolated from a diverse group of fungi including Aspergillus fumigatus, A. flavipes, A. versicolor, Chaetomium sp., and Penicillium thymicola. During our ongoing investigation for the bioactive secondary metabolites of marine-derived fungi [11–15], four new quinazolinone alkaloids, namely, aniquazolines A–D (1–4) (Figure 1), were isolated and elucidated from the culture of the fungus Aspergillus nidulans MA-143, which was obtained from the leaves of a mangrove plant Rhizophora stylosa. Details of the isolation, structure elucidation, and biological activity of compounds 1–4 are reported herein.

Figure 1. Structures of the isolated compounds 1–4 and reference compounds fumiquazoline C and chaetominine.

2. Results and Discussion

2.1. Structure Elucidation of the New Compounds 1–4

Compound 1 was obtained as a colorless crystal. Its molecular formula was determined as C_{26}H_{25}N_{3}O_{4} on the basis of HRESIMS, with 17 degrees of unsaturation. Analysis of the 1H NMR spectrum of 1 revealed the resonances of four triple-doublets at δ_{H} 7.88 (td, J = 7.9, 1.3 Hz, H-8), 7.61 (td, J = 7.9, 0.9 Hz, H-9), 7.31 (td, J = 7.7, 0.9 Hz, H-25) and 7.04 (td, J = 7.7, 0.9 Hz, H-26), two double-doublets at δ_{H} 7.75 (dd, J = 7.9, 0.9 Hz, H-7) and 8.18 (dd, J = 7.9, 1.3 Hz, H-10), and two doublets at δ_{H} 7.38 (d, J = 7.7 Hz, H-24) and 7.25 (d, J = 7.7 Hz, H-27) (Table 1), which indicated the presence of two 1,2-disubstituted phenyl groups (C-6 to C-11 and C-23 to C-28) in 1. Its 13C and DEPT NMR spectra showed signals for three methyls, one methylene, eight sp^2 and four sp^3 methines, as well as ten quaternary carbons including two oxygenated sp^3 carbons and three ester/amide carbonyl carbons (Table 2). A detailed NMR data comparison with those reported for fumiquazoline C, a quinazolinone alkaloid isolated from a fungal strain of Aspergillus fumigatus originally derived from the marine fish Pseudolabrus japonicus [2], revealed that the two compounds had the same carbon skeleton. Compound 1 differed from fumiquazoline C mainly at the presence of an isopropyl group (δ_{H} 2.09/δ_{C} 31.4, CH-29; δ_{H} 1.07/δ_{C} 17.9, CH_{3}-30; and δ_{H} 1.07/δ_{C} 18.5, CH_{3}-31) connected at C-20 in 1, as it was a methyl group (δ_{H} 1.06/δ_{C} 18.7, CH_{3}) in that of fumiquazoline C. This deduction was further verified by the 1H–1H COSY correlations from H-29 to H-20 and H_{3}-30/H_{2}-31 as well as by the observed HMBC correlations from H_{3}-31 to C-20, C-29, and C-30 and from NH-19 to C-29 as shown in Figure 2.
Table 1. $^1$H NMR (500 MHz) data of compounds 1–4 in DMSO-$d_6$ (δ in ppm).

| Position | 1 (J in Hz) | 2 (J in Hz) | 3 (J in Hz) | 4 (J in Hz) |
|----------|-------------|-------------|-------------|-------------|
| 2-NH     | 9.84, br s  | 8.61, br s  | 9.49, br s  | 8.30, s     |
| 3        | 4.94, q (6.5)| 3.38, dd (7.3, 2.8)| 5.81, d (6.5)| 5.94, dd (7.9, 1.3)|
| 4        |             | 3.38, dd (7.3, 2.8)| 5.81, d (6.5)| 5.94, dd (7.9, 1.3)|
| 7        | 7.75, dd (7.9, 0.9) | 7.66, d (7.8)  | 7.70, m     | 7.71, dd (7.9, 0.8) |
| 8        | 7.88, td (7.9, 1.3) | 7.82, t (7.8)  | 7.86, td (7.8, 1.2) | 7.87, td (7.9, 1.3) |
| 9        | 7.61, td (7.9, 0.9) | 7.53, t (7.8)  | 7.58, td (7.8, 1.2) | 7.59, td (7.9, 0.8) |
| 10       | 8.18, dd (7.9, 1.3) | 8.12, d (7.8)  | 8.16, dd (7.8, 1.2) | 8.18, dd (7.9, 1.3) |
| 14       | 5.36, dd (5.5, 1.5) | 5.58, dd (9.6, 4.3) | 5.44, dd (7.4, 6.5) | 4.86, dd (8.1, 5.3) |
| 15       | 2.98, dd (14.0, 5.5) | 2.59, dd (14.8, 9.6) | 2.61, dd (14.5, 7.4) | 3.01, dd (14.0, 8.1) |
| 16       | 1.91, s     | 1.59, d (6.5)  | 1.76, s     | 1.79, s     |
| 17-OH    |             | 5.67, br s    | 5.67, br s  | 5.45, br s *|
| 18       | 5.70, dd (6.0, 1.5) | 5.26, d (5.8)  | 5.31, dd (7.3, 1.5) | 5.82, s     |
| 19-NH    | 2.67, d (5.5) | 3.51, m      | 3.38, dd (7.3, 2.8)| 4.21, d (9.3) |
| 20       | 3.59, br d (5.5) | 3.55, br s    | 3.53, br s  | 4.21, d (9.3) |
| 24       | 7.38, d (7.7) | 7.35, d (7.8) | 7.34, d (7.6) | 7.47, d (7.4) |
| 25       | 7.31, td (7.7, 0.9) | 7.26, t (7.8)  | 7.27, td (7.6, 1.0) | 7.43, td (7.4, 1.2) |
| 26       | 7.04, td (7.7, 0.9) | 7.09, t (7.8)  | 7.15, td (7.6, 1.0) | 7.26, td (7.4, 1.2) |
| 29       | 2.09, dq (13.4, 6.8) | 1.99, m      | 1.98, m     | 2.45, m     |
| 30       | 1.07, d (6.8) | 0.93, d (6.8) | 0.91, d (6.6) | 1.15, d (6.7) |
| 31       | 1.07, d (6.8) | 0.96, d (6.8) | 0.92, d (6.6) | 1.12, d (6.7) |

* This exchangeable proton was detected in acetone-$d_6$.

Table 2. $^{13}$C NMR (125 MHz) data of compounds 1–4 in DMSO-$d_6$ (δ in ppm).

| Position | 1       | 2       | 3       | 4       |
|----------|---------|---------|---------|---------|
| 1        | 168.6, C | 168.9, C | 169.7, C | 164.8, C |
| 3        | 84.2, C  | 48.5, CH | 84.4, C  |         |
| 4        | 151.5, C | 153.3, C | 150.3, C | 146.7, CH|
| 6        | 146.6, C | 146.6, C | 146.0, C | 147.5, C |
| 7        | 127.8, CH| 126.9, CH| 127.3, CH| 127.1, CH|
| 8        | 134.6, CH| 134.4, CH| 134.6, CH| 134.6, CH|
| 9        | 127.5, CH| 126.7, CH| 127.4, CH| 127.3, CH|
| 10       | 126.4, CH| 126.4, CH| 126.4, CH| 126.1, CH|
| 11       | 120.5, C | 120.0, C | 120.1, C | 121.5, C |
| 12       | 158.8, C | 160.2, C | 160.5, C | 159.7, C |
| 14       | 52.7, CH | 51.8, CH | 52.6, CH | 55.6, CH |
| 15       | 33.7, CH$_2$ | 35.5, CH$_2$ | 39.1, CH$_2$ | 34.1, CH$_2$ |
| 16       | 23.7, CH$_3$ | 16.5, CH$_3$ | 20.3, CH$_3$ |         |
| 17       | 86.3, C  | 80.1, C  | 80.3, C  | 73.8, C  |
| 18       | 88.4, CH | 88.1, CH | 88.1, CH | 83.7, CH |
| 20       | 69.0, CH | 69.1, CH | 69.0, CH | 69.3, CH |
| 21       | 171.5, C | 172.1, C | 172.6, C | 173.8, C |
| 23       | 136.6, C | 137.2, C | 137.7, C | 140.2, C |
The relative configuration of compound 1 was determined by NOESY spectrum and by the X-ray experiment. The NOE correlations from H-16 to H-14 and H-18 as well as from H-18 to H-29 indicated the same orientation of these protons (Figure 3). The structure and relative configuration of compound 1 were confirmed by the single crystal X-ray diffraction analysis (Figure 4). The absolute configuration of 1 was deduced by chiral HPLC analysis of the degradation products of the acidic hydrolysates. The HPLC profile of the hydrolysates was compared with that of authentic standard to establish the configuration of the amino acid-derived unit as L-valine (Figure 5), corresponding to the S-configuration for C-20. The absolute configuration of compound 1 was therefore assigned to be 3R, 14R, 17R, 18R, and 20S, which was identical to that of fumiquinazoline C [2]. The ECD (Electronic Circular Dichroism) spectrum of 1 showed negative Cotton Effect (CE) at 199, 238, 258, and 303 nm, and positive CE at 216 nm (Figure 6). The structure of 1 was thus elucidated and it was named as aniquinazoline A.

Table 2. Cont.

|   |   |   |   |   |
|---|---|---|---|---|
| 24 | 114.3, CH | 115.1, CH | 115.2, CH | 114.2, CH |
| 25 | 129.7, CH | 128.8, CH | 128.6, CH | 130.0, CH |
| 26 | 125.1, CH | 124.6, CH | 124.6, CH | 125.1, CH |
| 27 | 126.2, CH | 125.4, CH | 125.2, CH | 124.5, CH |
| 28 | 137.4, C  | 138.7, C  | 138.8, C  | 134.9, C  |
| 29 | 31.4, CH  | 31.0, CH  | 31.0, CH  | 28.2, CH  |
| 30 | 17.9, CH3 | 17.6, CH3 | 17.4, CH3 | 18.6, CH3 |
| 31 | 18.5, CH3 | 18.6, CH3 | 18.5, CH3 | 20.1, CH3 |

Figure 2. Key $^1$H–$^1$H COSY (bold lines) and HMBC (red arrows) correlations of compounds 1–4.
**Figure 3.** NOESY correlations of compounds 1–4.

**Figure 4.** X-ray structure of compound 1 (Note: A different numbering system is used for the structure in the text).
Compound 2 was obtained as yellowish solid. The HRESIMS experiment established its molecular formula \( \text{C}_{26}\text{H}_{27}\text{N}_{5}\text{O}_{4} \) (16 degrees of unsaturation), with two more \( H \)-atom than that of 1. The \(^1\text{H}\) and \(^{13}\text{C}\) NMR data of 2 were very similar to those of 1 (Tables 1 and 2), indicating that they shared the same carbon skeleton. However, the oxygenated \( \text{sp}^3 \) quaternary carbon at \( \delta_{\text{C}} 84.2 \) (C-3) in the \(^{13}\text{C}\) NMR spectrum of 1 disappeared in that of 2. Instead, signals for a methine group \( (\delta_{\text{H}} 4.94/\delta_{\text{C}} 48.5, \text{CH}-3) \) were...
observed in the NMR spectra of 2 (Tables 1 and 2). Accordingly, the singlet methyl signal at δH 1.91 (H3-16) in the 1H NMR spectrum of 1 was replaced by a doublet methyl group at δH 1.59 (J = 6.5 Hz) in that of 2, and an exchangeable OH proton at δH 5.67 (br s, 17-OH) was observed (Table 1). This OH group was attached at C-17 on the basis of HMBC correlations from the OH proton to C-15 (δC 35.5, CH2), C-17 (δC 80.1, C), and C-27 (δC 125.4, CH) (Figure 2). The 1H–1H COSY and HMBC correlations shown in Figure 2 confirmed the planar structure of 2. The relative configuration of compound 2 was determined by NOESY spectrum as well as by comparing the 1H-NMR J-values with that of fumiquinazolines A and B [2]. The observed NOE correlations from H-18 to H-14 and H-29 and from H-14 to H-3 and 17-OH, indicated them on the same face of the molecule (Figure 3). In contrast to compound 1, no NOE correlations could be observed from H-16 to H-14 and H-18. Instead, NOE correlation from H-14 to H-3 was observed in the NOESY spectrum of 2 (see Figure 3 as well as Figure S12b in the Supplementary Materials). In the reference report, a large coupling constant (J = 4.9 Hz) for H-3 and NH-2 was observed in fumiquinazoline B, whereas its C-3 epimer, fumiquinazoline A, showed a very small coupling constant (J = 0.3 Hz) [2]. In the case of compound 2, the proton NH-2 was observed as a broad singlet (Table 1), which means the coupling constant between H-3 and NH-2 was very small, thus suggesting the configuration at C-3 is close to that of fumiquinazoline A. The above data suggested that the C3-O-C17 ether ring in 1 was opening in that of 2, and the configuration of C-3 changed during the ring-opening process. To substantiate this, compound 1 was reduced with NaBH4 in THF at room temperature for 40 min and the resulting product was revealed to be identical to 2 by co-TLC analysis. The 1H-NMR and 1H–1H COSY as well as NOESY spectra also showed that the reduced product of 1 was the same as that of compound 2 (see Supplementary Material). However, it was described in the reference that reduction of fumiquinazoline C yielded fumiquinazoline A without C-3 configuration change [2], and this differs from our observation as discussed above. Unfortunately, no NOESY experiment was performed and described for the reducing product of fumiquinazoline C [2], which would have helped give solid evidence to clarify the problem. Based on the above data, the relative configurations between C-3 and C-14 of fumiquinazoline A [2] should be reconsidered.

The absolute configuration of C-20 in compound 2 was also assigned as S based on the chiral HPLC analysis of its acidic hydrolysates (Figure 5) and the absolute configurations of other chiral centers in 2 were therefore assigned as 3R, 14R, 17R, and 18R. The structure of 2 was thus elucidated and named as aniquinazoline B.

Compound 3 was obtained as a yellowish solid. Its molecular formula was determined to be C28H27N2O5 (16 degrees of unsaturation) on the basis of HRESIMS data, with one more O-atom than that of 2. The assignments of the NMR data of 3 (Tables 1 and 2) matched well with that of the corresponding signals for 2, except for the presence of an OH group at C-3 in 3, which was consistent with the difference in molecular formula. Accordingly, the non-oxygenated CH signals resonated at δH 4.94/δC 48.5 (CH-3) in the NMR spectra of 2 and disappeared in that of 3. Instead, an oxygenated quaternary carbon at δC 84.4 (C-3) was observed in the 13C NMR spectrum of 3 (Table 2). Correspondingly, the methyl doublet signal at δH 1.59 (J = 6.5 Hz, H3-16) in the 1H NMR spectrum of 2 was replaced by a downfield singlet at δH 1.76 (H2-16) in that of 3 (Table 1). The 1H–1H COSY and HMBC correlations shown in Figure 2 confirmed the planar structure of 3.

The relative configuration of compound 3 was determined by NOESY spectrum. The NOE correlations from H-18 to H-29 and 17-OH and from 17-OH to H-14 revealed these protons were on the
same face of the molecule (Figure 3). The relative configuration at C-3 was assigned as being the same as that of 2 from the biogenetic point of view. The absolute configuration of C-20 was also determined as S by the chiral HPLC analysis of the acidic hydrolysates of 3 (Figure 5). Consequently, the absolute configuration of compound 3 was assigned as 3S, 14R, 17R, 18R, and 20S. The very similar ECD spectra for compounds 2 and 3 (Figure 6) supported the above assignment. The structure of compound 3 was thus determined and was named aniquinazoline C.

Compound 4 was isolated as a yellowish solid. Its molecular formula was determined as C24H22N4O4 by HRESIMS data. Detailed comparison of NMR data of compound 4 (Tables 1 and 2) with those of chaetominine, a cytotoxic alkaloid produced by endophytic Chaetomium sp. IFB-E015 originally isolated from the apparently healthy Adenophora axilliflora leaves [5], suggested that they shared the same carbon skeleton. The main difference was that the methyl group at C-20 in chaetominine was replaced by an isopropyl group in 4. This deduction was verified by 1H–1H COSY and HMBC correlations as shown in Figure 2. The relative configuration of C-20 was assigned as S on the basis of the chiral HPLC analysis of the acidic degradation product of 4 (Figure 5). Thus the absolute configuration of compound 4 was determined as 14R, 17S, 18S, and 20S, and it was named aniquinazoline D.

2.2. Biological Activities of the Isolated Compounds

The isolated compounds 1–4 were examined for brine shrimp toxicity, antitumor, and antibacterial activities. Compounds 1–4 showed potent lethality against brine shrimp with LD50 values of 1.27, 2.11, 4.95 and 3.42 μM, respectively, which were stronger than that of the positive control colchicine (with LD50 value of 88.4 μM). Compounds 1–4 were also evaluated for antitumor and antibacterial activity, but none of them displayed inhibitory activity against four cell lines (BEL-7402, MDA-MB-231, HL-60, and K562) and two bacteria (Escherichia coli and Staphylococcus aureus).

3. Experimental Section

3.1. General

The melting point was determined with an SGW X-4 micro-melting-point apparatus. The optical rotations were measured on an Optical Activity A-55 polarimeter. UV data were obtained on a Lengguang Gold S54 spectrophotometer. The 1H, 13C, and 2D NMR spectroscopic data were acquired on Bruker Advance 500 spectrometers. Mass spectra were measured on a VG Autospec 3000 mass spectrometer. HPLC analysis was performed on a Dionex HPLC System equipped with a P680 pump, an ASI-100 automated sample injector, a TCC-100 column oven, a UV-DAD 340U detector, and a Dionex Acclaim ODS column (4.6 × 250 mm, 5 μm). Semi-preparative HPLC was operated on a Dionex UltiMate U3000 system using an Agilent Prep RP-18 column (21.2 × 250 mm, 10 μm) with UV detection. A Phenomenex-Chirex 3126 N,S-dioctyl-(D)-penicillamine column (250 × 4.60 mm, 5 μm) was used for chiral HPLC analysis. Column chromatography (CC) was performed with silica gel (200–300 mesh, Qingdao Marine Chemical Factory), Lobar LiChroprep RP-18 (40–63 μm; Merck), and Sephadex LH-20 (18–110 μm, Merck).
3.2. Fungal Material

The fungus *Aspergillus nidulans* MA-143 was isolated from the leaves of marine mangrove plant *Rhizophora stylosa*. The fungus grew slowly on potato dextrose agar (PDA) plate and turned from white to green mycelia within 5 days. The fungus was identified by sequence analysis of the ITS region of its rDNA as described previously [16] and the sequence data obtained from the fungus have been deposited in GenBank with accession number JQ839285. The strain is preserved at the Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences.

3.3. Fermentation

The fermentation was statically carried out in liquid potato-dextrose broth medium (PDB) (1000 mL seawater, 20 g glucose, 5 g peptone, 3 g yeast extract, pH 6.5–7.0, liquid medium/flask = 300 mL) in 1 L Erlenmeyer flasks for 30 days at room temperature.

3.4. Extraction and Isolation

The fermented whole broth (100 flasks) was filtered through cheesecloth to separate the culture broth and mycelia, which were extracted exhaustively with EtOAc and MeOH, respectively. Since the chemical profiles of the two extracts were almost identical, they were combined and concentrated to afford the crude extract (31.0 g) for further separation. The crude extract was subjected to silica gel vacuum liquid chromatography (VLC) eluting with mixed solvents of increasing polarity (petroleum ether-EtOAc, 5:1 to 1:1, and then CHCl3–MeOH, 20:1 to 0:1) to yield 7 fractions (Fr.1 to Fr.7). Fraction 2 (11.0 g) was further separated to seven subfractions (Fr.2.1–2.7) by CC on silica gel eluted with CHCl3–MeOH (100:1 to 5:1). Fr.2.1 (7.0 g) was subjected to CC on Lobar LiChroprep C18 eluting with MeOH-H2O gradient (1:9 to 1:0) and then further purified by semi-preparative HPLC (MeOH–H2O 7:3, 16 mL/min) to afford 2 ($t_R = 14.6$ min, 5.2 mg). Fr.2.2 (3.0 g) was subjected to CC on silica gel eluted with CHCl3–MeOH (100:1 to 5:1) and Sephadex LH-20 (petroleum ether–CHCl3–MeOH, 5:5:1), and then further purified by semi-preparative HPLC (MeOH–H2O 7:3, 16 mL/min) to obtain 1 ($t_R = 15.8$ min, 20.0 mg), 3 ($t_R = 13.5$ min, 5.5 mg), and 4 ($t_R = 10.5$ min, 7.7 mg).

Aniquinazoline A (1): colorless crystal; mp 243–245 °C; $[\alpha]_{D}^{20} = -13$ (c 0.30, MeOH); UV (MeOH) $\lambda_{\max}$ (log $\varepsilon$) 200 (4.41), 218 (4.26), 245 (3.97), 270 (3.82), 297 (3.32), 305 (3.37) nm; CD $\lambda_{\max}$ (Δ$\varepsilon$) 199 (−11.33), 216 (+21.60), 238 (−4.92), 258 (−4.52), 303 (−2.63) nm; $^1$H and $^{13}$C NMR data, see Tables 1 and 2; ESIMS $m/z$ 472 [M + H]$^+$; HRESIMS $m/z$ 472.1982 [M + H]$^+$ (calcld for C$^{20}$H$^{26}$N$^5$O$^4_+$, 472.1985, Δ 0.3 ppm).

Aniquinazoline B (2): yellowish solid; $[\alpha]_{D}^{20} = -118$ (c 0.28, MeOH); UV (MeOH) $\lambda_{\max}$ (log $\varepsilon$) 202 (4.46), 225 (4.33), 243 (4.03), 304 (3.35) nm; CD $\lambda_{\max}$ (Δ$\varepsilon$) 197 (−10.99), 210 (+21.55), 233 (−19.63), 304 (−1.59) nm; $^1$H and $^{13}$C NMR data, see Tables 1 and 2; ESIMS $m/z$ 474 [M + H]$^+$; HRESIMS $m/z$ 474.2143 [M + H]$^+$ (calcld for C$^{29}$H$^{28}$N$^5$O$^4_+$, 474.2141, Δ 0.2 ppm).

Aniquinazoline C (3): yellowish solid; $[\alpha]_{D}^{20} = -19$ (c 0.28, MeOH); UV (MeOH) $\lambda_{\max}$ (log $\varepsilon$) 200 (4.63), 214 (4.51), 246 (4.14), 271 (4.01), 290 (3.70), 301 (3.61) nm; CD $\lambda_{\max}$ (Δ$\varepsilon$) 199 (−9.37), 212...
(+24.53), 235 (−21.94), 303 (−2.65) nm; $^1$H and $^{13}$C NMR data, see Tables 1 and 2; ESIMS $m/z$ 490 [M + H]$^+$; HRESIMS $m/z$ 490.2084 [M + H]$^+$ (calcd for C$_{29}$H$_{28}$N$_5$O$_5$ $^+$, 490.2090, $\Delta$ 0.6 ppm).

Aniquinazoline D (4): yellowish solid; $[\alpha]$$_D$$^2$ $-$33 (c 0.37, MeOH); UV (MeOH) $\lambda_{\text{max}}$ (log $e$) 200 (6.06), 218 (5.91), 246 (5.61), 268 (5.52), 298 (4.98), 312 (4.92) nm; CD $\lambda_{\text{max}}$ (A$e$) 201 (−33.36), 218 (+13.62), 244 (−9.78), 276 (+1.17), 301 (−2.08) nm; $^1$H and $^{13}$C NMR data, see Tables 1 and 2; ESIMS $m/z$ 431 [M + H]$^+$; HRESIMS $m/z$ 431.1710 [M + H]$^+$ (calcd for C$_{24}$H$_{23}$N$_4$O$_4$$^+$, 431.1719, $\Delta$ 0.9 ppm).

3.5. X-ray Crystallographic Analysis of Compounds 1

All crystallographic data [17] were collected on a Bruker Smart-1000 CCD diffractometer equipped with a graphite-monochromatic Mo-K$\alpha$ radiation ($\lambda = 0.71073$ Å) at 298(2) K. The data were corrected for absorption by using the program SADABS [18]. The structure was solved by direct methods with the SHELXTL software package [19]. All non-hydrogen atoms were refined anisotropically. The H atoms were located by geometrical calculations, and their positions and thermal parameters were fixed during the structure refinement. The structure was refined by full-matrix least-squares techniques [20].

Crystal data for compound 1: C$_{27}$H$_{29}$N$_5$O$_5$, F.W. = 503.55, one molecule containing a CH$_3$OH solvent molecule in the unit, monoclinic space group P2(1), unit cell dimensions $a = 11.3860(5)$ Å, $b = 7.8898(3)$ Å, $c = 13.6963(5)$ Å, $V = 1230.18(8)$ Å$^3$, $\alpha = \gamma = 90^\circ$, $\beta = 91.044(3)^\circ$, $Z = 2$, $d_{\text{calcd}} = 1.359$ mg/m$^3$, crystal dimensions 0.45 × 0.40 × 0.32 mm, $\mu = 0.096$ mm$^{-1}$, $F(000) = 532$. The 7506 measurements yielded 4172 independent reflections after equivalent data were averaged, and Lorentz and polarization corrections were applied. The final refinement gave $R_1 = 0.0332$ and wR$_2 = 0.0778[I > 2\sigma(I)]$.

3.6. Amino Acid Analysis

Compounds 1 (1.3 mg), 2 (0.9 mg), 3 (0.8 mg), and 4 (1.1 mg) were each solved in 10 mL 6 N HCl and heated at 110 $^\circ$C for 24 h in sealed tubes. The solutions were then evaporated to dryness under reduced pressure. Each sample, including the standard amino acid L-val and D-val, was solved in 1 mL of eluting solvent (2 mM CuSO$_4$·5H$_2$O, with 5 mL CH$_3$CN in every 100 mL solvent) and was concentrated at a speed of 12,000 rpm. Chiral HPLC analysis was carried out using a Phenomenex-Chirex-3126 column at 254 nm with flow rate 1.0 mL/min at 40 $^\circ$C. The HPLC analysis showed that the products of acidic hydrolysis of 1–4 contained the identical amino acid, which have the same retention time as that of the standard L-val. The results established the chiral center of the valine moiety in the structure of the four compounds to be $S$-configuration (Figure 5).

3.7. Reduction of Compound 1

Compound 1 (6.8 mg) was dissolved in 1.0 mL THF (tetrahydrofuran), and NaBH$_4$ (5.0 mg) was added to the solution. The mixture was stirred at room temperature for 40 min and then concentrated under reduced pressure. The residue was diluted with water, extracted by CH$_2$Cl$_2$ and then evaporated. The reducing product (1.5 mg) was obtained from the extract by preparative TLC (CHCl$_3$–MeOH, 30:1). Compound 2 and the reducing product were evidenced to be identical on the basis of co-TLC and NMR data analysis (see Supplementary Material, Figures S28–S30).
3.8. Brine Shrimp Toxicity

Brine shrimp (Artemia salina) toxicity of the isolated compounds was determined as described previously [21]. Colchicine was used as a positive control.

3.9. Cytotoxicity Assay

The cytotoxic activity against BEL-7402 (human hepatocellular carcinoma), MDA-MB-231 (human breast carcinoma), HL-60 (human promyelocytic leukemia cells), and K562 (human acute myelocytic leukemia cell line) cell lines were determined according to previously reported methods [22].

3.10. Antibacterial Assay

Antibacterial assay against E. coli and S. aureus was carried out using the well diffusion method [23]. Chloromycetin was used as a positive control.

4. Conclusions

Four new quinazolinone alkaloids (1–4) were isolated from the mangrove-derived endophytic fungus Aspergillus nidulans MA-143. The structures and relative configurations were determined on the interpretation of the NMR data and the absolute configuration of all compounds was determined by chiral HPLC analysis of the acid hydrolysates. Compounds 1–4 exhibited potent brine shrimp toxicity with LD50 values of 1.27, 2.11, 4.95 and 3.42 μM, respectively.

Acknowledgments

This work was financially supported by Ministry of Science and Technology (2013AA092901 and 2010CB833802) and by National Natural Science Foundation of China (31270403).

Conflict of Interest

The authors declare no conflict of interest.

References

1. Mhaske, S.B.; Argade, N.P. The chemistry of recently isolated naturally occurring quinazolinone alkaloids. Tetrahedron 2006, 62, 9787–9826.
2. Takahashi, C.; Matsushita, T.; Doi, M.; Minoura, K.; Shingu, T.; Kumeda, Y.; Numata, A. Fumiquinazolines A–G, novel metabolites of a fungus separated from a Pseudolabrus marine fish. J. Chem. Soc. Perkin. Trans. I 1995, 2345–2353; doi:10.1039/P19950002345.
3. Larsen, T.O.; Frydenvang, K.; Frisvad, J.C.; Christophersen, C. UV-guided isolation of alantrypinone, a novel Penicillium alkaloid. J. Nat. Prod. 1998, 61, 1154–1157.
4. Numata, A.; Takahashi, C.; Matsushita, T.; Miyamoto, T.; Kawai, K.; Usami, Y.; Matsumura, E.; Inoue, M.; Ohishi, H.; Shingu, T. Fumiquinazolines, novel metabolites of a fungus isolated from a saltfish. Tetrahedron Lett. 1992, 33, 1621–1624.
5. Jiao, R.H.; Xu, S.; Liu, J.Y.; Ge, H.M.; Ding, H.; Xu, C.; Zhu, H.L.; Tan, R.X. Chaetominine, a cytotoxic alkaloid produced by endophytic Chaetomium sp. IFB-E015. *Org. Lett.* **2006**, *8*, 5709–5712.

6. Zhuang, Y.B.; Teng, X.C.; Wang, Y.; Liu, P.P.; Li, G.Q.; Zhu, W.M. New quinazolinone alkaloids within rare amino acid residue from coral-associated fungus, *Aspergillus versicolor* LCJ-5-4. *Org. Lett.* **2011**, *13*, 1130–1133.

7. Fremlin, L.J.; Piggott, A.M.; Lacey, E.; Capon, R.J. Cottoq uinazoline A and cotteslosins A and B, metabolites from an Australian marine-derived strain of *Aspergillus versicolor*. *J. Nat. Prod.* **2009**, *72*, 666–670.

8. Barrow, C.J.; Sun, H.H. Spiroquinazoline, a novel substance P inhibitor with a new carbon skeleton, isolated from *Aspergillus flavipes*. *J. Nat. Prod.* **1994**, *57*, 471–476.

9. Li, X.J.; Zhang, Q.; Zhang, A.L.; Gao, J.M. Metabolites from *Aspergillus fumigatus*, an endophytic fungus associated with *Melia azedarach*, and their antifungal, antifeedant, and toxic Activities. *J. Agric. Food Chem.* **2012**, *60*, 3424–3431.

10. Ames, B.D.; Haynes, S.W.; Gao, X.; Evans, B.S.; Kelleher, N.L.; Tang, Y.; Walsh, C.T. Complexity generation in fungal peptidyl alkaloid biosynthesis: Oxidation of fumiquinazoline A to the heptacyclic hemiaminal fumiquinazoline C by the flavoenzyme Af12070 from *Aspergillus fumigatus*. *Biochemistry* **2011**, *50*, 8756–8769.

11. Sun, H.F.; Li, X.M.; Meng, L.; Cui, C.M.; Gao, S.S.; Li, C.S.; Huang, C.G.; Wang, B.G. Asperolides A–C, tetranorlabdane diterpenoids from the marine alga-derived endophytic fungus *Aspergillus wentii* EN-48. *J. Nat. Prod.* **2012**, *75*, 148–152.

12. Du, F.Y.; Li, X.M.; Li, C.S.; Shang, Z.; Wang, B.G. Cristatumins A–D, new indole alkaloids from the marine-derived endophytic fungus *Eurotium cristatum* EN-220. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 4650–4653.

13. Li, C.S.; An, C.Y.; Li, X.M.; Gao, S.S.; Cui, C.M.; Sun, H.F.; Wang, B.G. Triazole and dihydroimidazole alkaloids from the marine sediment-derived fungus *Penicillium paneum* SD-44. *J. Nat. Prod.* **2011**, *74*, 1331–1334.

14. Gao, S.S.; Li, X.M.; Du, F.Y.; Li, C.S.; Proksch, P.; Wang, B.G. Secondary metabolites from a marine-derived endophytic fungus *Penicillium chrysogenum* QEN-24S. *Mar. Drugs* **2011**, *9*, 59–70.

15. Liu, D.; Li, X.M.; Meng, L.; Li, C.S.; Gao, S.S.; Shang, Z.; Proksch, P.; Huang, C.G.; Wang, B.G. Nigerapyrones A–H, α-pyrone derivatives from the marine mangrove-derived endophytic fungus *Aspergillus niger* MA-132. *J. Nat. Prod.* **2011**, *74*, 1787–1791.

16. Wang, S.; Li, X.M.; Teuscher, F.; Li, D.L.; Diesel, A.; Ebel, R.; Proksch, P.; Wang, B.G. Chaetopyranin, a benzaldehyde derivative, and other related metabolites from *Chaetomium globosum*, an endophytic fungus derived from the marine red alga *Polysiphonia urceolata*. *J. Nat. Prod.* **2006**, *69*, 1622–1625.

17. Cambridge Crystallographic Data Centre (CCDC). Available online: http://www.ccdc.cam.ac.uk/data_request/cif (accessed on 5 March 2013).

18. Sheldrick, G.M. *SADABS, Software for Empirical Absorption Correction*; University of Göttingen: Göttingen, Germany, 1996.
19. Sheldrick, G.M. *SHELXTL, Structure Determination Software Programs*; Bruker Analytical X-ray System Inc.: Madison, WI, USA, 1997.

20. Sheldrick, G.M. *SHELXL-97 and SHELXS-97, Program for X-ray Crystal Structure Solution and Refinement*; University of Göttingen: Göttingen, Germany, 1997.

21. Gerwick, W.H.; Proteau, P.J.; Nagle, D.G.; Hamel, E.; Blokhin, A.; Slate, D.L. Structure of curacin A, a novel antimitotic, antiproliferative, and brine shrimp toxic natural product from the marine Cyanobacterium *Lyngbya majuscula*. *J. Org. Chem.* 1994, 59, 1243–1245.

22. Bergeron, R.J.; Cavanaugh, P.F., Jr.; Kline, S.J.; Hughes, R.G., Jr.; Elliott, G.T.; Porter, C.W. Antineoplastic and antiviral activity of spermidine catecholamide iron chelators. *Biochem. Biophys. Res. Commun.* 1984, 121, 848–854.

23. Al-Burtamani, S.K.S.; Fatope, M.O.; Marwh, R.G.; Onifade, A.K.; Al-Saidi, S.H. Chemical composition, antibacterial and antifungal activities of the essential oil of *Haplophyllum tuberculatum* from Oman. *J. Ethnopharmacol.* 2005, 96, 107–112.

© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).